Wegovy won’t be in Canadian public drug plans as Novo Nordisk refuses talks

• Negotiations for the inclusion of Wegovy, a weight-loss drug developed by Novo Nordisk, in Canadian public drug plans have stalled as the company has refused to engage in discussions. This decision leaves many Canadians without access to this medication under public health coverage.
• The refusal to negotiate is significant for Novo Nordisk, as it limits the potential market for Wegovy in Canada, impacting the company's revenue and growth prospects in a competitive pharmaceutical landscape focused on obesity treatments.
• This development reflects ongoing challenges in the pharmaceutical industry regarding drug pricing and accessibility, particularly for weight-loss medications. As Novo Nordisk faces setbacks with Wegovy's efficacy in treating conditions like Alzheimer's, the company is under pressure to innovate and address side effects associated with existing treatments, while also competing with emerging obesity drugs.

— via World Pulse Now AI Editorial System